Actively Recruiting
Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban
Led by General Hospital of Shenyang Military Region · Updated on 2025-12-09
870
Participants Needed
1
Research Sites
111 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
It remains uncertain whether intravenous tirofiban administered before endovascular thrombectomy could improve disability severity for patients with LVO due to intracranial atherosclerosis.The current study aimed to assess the efficacy and safety of administering intravenous tirofiban before endovascular thrombectomy for improving clinical outcomes in patients with anterior circulation LVO due to intracranial atherosclerosis.
CONDITIONS
Official Title
Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age �3E�3D 18 years
- Anterior circulation large vessel occlusion confirmed by CTA or MRA
- Eligible for endovascular treatment within 12 hours of symptom onset
- Large artery atherosclerosis highly suspected based on medical history, clinical presentation, and imaging
- Baseline NIH Stroke Scale score �3E�3D 6
- Baseline ASPECTS score �3E�3D 6 on CT
- Pre-stroke modified Rankin Scale score �3C�3D 2
- Signed informed consent by patient or legally authorized representative
You will not qualify if you...
- History of atrial fibrillation or atrial flutter, or ECG showing atrial flutter or atrial fibrillation before randomization or after admission
- Hemorrhagic stroke or history of bleeding within one month
- Intracranial aneurysms, malformations, tortuous arteries hindering thrombectomy, or brain tumors with space-occupying effect
- Use of dual antiplatelet drugs, direct oral anticoagulants, warfarin, or other bleeding risk drugs within one week
- Severe uncontrolled hypertension (systolic > 200 mmHg or diastolic > 110 mmHg)
- Deficiency of anticoagulant factors, INR > 1.7, or platelet count < 90�d7 10�b9/L
- Severe renal insufficiency or advanced disease with life expectancy less than 6 months
- Pregnancy or lactation
- Allergy to drugs or contrast agents
- Participation in other clinical trials
- Any other condition deemed unsuitable by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
General Hospital of Northern Theater Command
Shenyang, Liaoning, China, 110016
Actively Recruiting
Research Team
H
Hui-Sheng Chen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here